Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The findings suggest that, in addition to women diagnosed with GDM who require antidiabetic medications, maternal ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Treatment for a rash on or inside the buttocks may include a combination of creams, self-care, or antivirals. Find a list of ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...